# everlinQ endoAVF Post Market Study

> **NCT02682420** · NA · TERMINATED · sponsor: **C. R. Bard** · enrollment: 100 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DEVICE:** everlinQ endoAVF System

## Key facts

- **NCT ID:** NCT02682420
- **Lead sponsor:** C. R. Bard
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-20
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 100 (ACTUAL)
- **Why stopped:** Company acquisition
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02682420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02682420, "everlinQ endoAVF Post Market Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02682420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*